Pay in 4 interest-free payments of $7.37 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
A deficiency can lead to fatigue, muscle weakness, and a significant loss of appetite
About Tirzepatide (LY3298176) Tirzepatide is a novel dual GIP/GLP-1 receptor agonist, currently under investigation for its potential role in metabolic and weight-related research applications
While safety studies for other indications are still pending, studies into using tirzepatide as a treatment of obesity in adults (the SURMOUNT program), have already yielded positive outcomes [12, 13]
Advice from our doctors plus valuable savings, sent right to your inbox
We dont provide shortcuts that will give you only temporary relief
The 2026 Delphi Consensus confirms WHtR is much more accurate than the Body Mass Index (BMI) for lipoedema patients, as it accounts for the disproportionate fat carried on the lower body without automatically categorising the patient as obese.
US$ 22.06
US$ 21.25
US$ 21.27
US$ 25.88
US$ 21.49
